Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP5 | Q01469 | 3/20 | 0.45 |
| ▸ | FABP7 | O15540 | 2/20 | 0.45 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.35 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.35 |
| ▸ | PTGFR | P43088 | 1/20 | 0.35 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.35 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.35 |
| ▸ | PTGIR | P43119 | 1/20 | 0.35 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.35 |
| ▸ | PYGL | P06737 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16634841 | 0.87 | SMN1; SMN2 (0.46) | FABP5FABP7KIF11KMT2ASMN1; SMN2 | |
| SCHEMBL5264305 | 0.86 | SMN1; SMN2 (0.55) | FABP5FABP7KMT2ASMN1; SMN2HIF1A | |
| SCHEMBL27522574 | 0.86 | SMN1; SMN2 (0.55) | FABP5FABP7KMT2ASMN1; SMN2HIF1A | |
| SCHEMBL29019464 | 0.86 | SMN1; SMN2 (0.55) | FABP5FABP7KMT2ASMN1; SMN2HIF1A | |
| SCHEMBL31351931 | 0.85 | KMT2A (0.41) | FABP5FABP7KMT2ASMN1; SMN2HIF1A | |
| SCHEMBL29663619 | 0.81 | FABP5 (0.44) | FABP5FABP7KMT2AEPHX2TBXA2R | |
| SCHEMBL1311053 | 0.81 | FABP5 (0.44) | FABP5FABP7KMT2ASMN1; SMN2HIF1A | |
| SCHEMBL29019449 | 0.81 | MGLL (0.41) | FABP5FABP7KMT2ASMN1; SMN2HIF1A | |
| SCHEMBL29019448 | 0.81 | MGLL (0.41) | FABP5FABP7KMT2ASMN1; SMN2HIF1A | |
| SCHEMBL31522719 | 0.80 | HIF1A (0.44) | FABP5FABP7KMT2ASMN1; SMN2HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220185846-A1 | METHODS FOR SYNTHESIZING BETA-HOMOAMINO ACIDS | PROTAGONIST THERAPEUTICS, INC. | 2022-06-16 | — | — | US | disclosed |
| US-20220162261-A1 | NOVEL a4B7 PEPTIDE MONOMER AND DIMER ANTAGONISTS | PROTAGONIST THERAPEUTICS, INC. | 2022-05-26 | — | — | US | disclosed |
| US-11111272-B2 | α4α7 peptide monomer and dimer antagonists | PROTAGONIST THERAPEUTICS, INC. (US) | 2021-09-07 | — | — | US | disclosed |
| EP-3200812-B1 | NOVEL ALPHA4BETA7 PEPTIDE MONOMER AND DIMER ANTAGONISTS | PROTAGONIST THERAPEUTICS INC (US) | 2020-11-25 | — | — | EP | disclosed |
| US-20200308229-A1 | NOVEL a4B7 PEPTIDE MONOMER AND DIMER ANTAGONISTS | PROTAGONIST THERAPEUTICS, INC. | 2020-10-01 | — | — | US | disclosed |
| US-10301371-B2 | Cyclic monomer and dimer peptides having integrin antagonist activity | PROTAGONIST THERAPEUTICS, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20180105572-A1 | NOVEL CYCLIC MONOMER AND DIMER PEPTIDES HAVING INTEGRIN ANTAGONIST ACTIVITY | PROTAGONIST THERAPEUTICS, INC. | 2018-04-19 | — | — | US | disclosed |
| US-9518091-B2 | A4B7 peptide monomer and dimer antagonists | PROTAGONIST THERAPEUTICS, INC. | 2016-12-13 | — | — | US | disclosed |
| US-20160159862-A1 | NOVEL a4B7 PEPTIDE MONOMER AND DIMER ANTAGONISTS | PROTAGONIST THERAPEUTICS, INC. | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159862-A1 | NOVEL a4B7 PEPTIDE MONOMER AND DIMER ANTAGONISTS | EPCAM, VCAM1, ITGB7 | FABP5 583/4885FABP7 139/4885KIF11 2484/4885 |
| US-20200308229-A1 | NOVEL a4B7 PEPTIDE MONOMER AND DIMER ANTAGONISTS | EPCAM, VCAM1, ITGB7 | FABP5 583/4885FABP7 139/4885KIF11 2484/4885 |
| US-10301371-B2 | Cyclic monomer and dimer peptides having integrin antagonist activity | EPCAM, VCAM1, ICAM1 | FABP5 1511/4885FABP7 810/4885KIF11 4269/4885 |
| US-20180105572-A1 | NOVEL CYCLIC MONOMER AND DIMER PEPTIDES HAVING INTEGRIN ANTAGONIST ACTIVITY | VCAM1, EPCAM, ICAM1 | FABP5 1679/4885FABP7 709/4885KIF11 4217/4885 |
| US-11111272-B2 | α4α7 peptide monomer and dimer antagonists | VCAM1, EPCAM, NECTIN4 | FABP5 525/4885FABP7 187/4885KIF11 3071/4885 |
| US-20220185846-A1 | METHODS FOR SYNTHESIZING BETA-HOMOAMINO ACIDS | PSMA7, ITGB7, SCN7A | FABP5 1359/4885FABP7 61/4885KIF11 2580/4885 |
| US-20220162261-A1 | NOVEL a4B7 PEPTIDE MONOMER AND DIMER ANTAGONISTS | EPCAM, VCAM1, ITGB7 | FABP5 583/4885FABP7 139/4885KIF11 2484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.